BlackRock Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

BlackRock Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.7M	Buy	60,785 +11,692	+24%	+$412K	﹤0.01%	1377
2016 Q3	$1.77M	Buy	49,093 +32,911	+203%	+$706K	﹤0.01%	1521
2016 Q2	$222K	Sell	16,182 -33,565	-67%	-$491K	﹤0.01%	2547
2016 Q1	$955K	Buy	49,747 +4,332	+10%	+$91.7K	﹤0.01%	1762
2015 Q4	$1.59M	Sell	45,415 -217,211	-83%	-$14M	﹤0.01%	1501
2015 Q3	$24.2M	Buy	262,626 +8,336	+3%	+$721K	0.03%	473
2015 Q2	$22.3M	Buy	254,290 +26,491	+12%	+$2.27M	0.02%	491
2015 Q1	$16.9M	Sell	227,799 -85,463	-27%	-$6.04M	0.02%	619
2014 Q4	$17.5M	Buy	313,262 +1,456	+0.5%	+$76.5K	0.02%	592
2014 Q3	$14.1M	Buy	311,806 +296,363	+1,919%	+$12.4M	0.01%	673
2014 Q2	$639K	Sell	15,443 -8,034	-34%	-$414K	﹤0.01%	1829
2014 Q1	$1.63M	Buy	23,477 +10,170	+76%	+$747K	﹤0.01%	1263
2013 Q4	$802K	Sell	13,307 -80,469	-86%	-$4.38M	﹤0.01%	1668
2013 Q3	$5.7M	Sell	93,776 -115,051	-55%	-$8.16M	0.01%	947
2013 Q2	$14M	Buy	+208,827	New	+$9.39M	0.01%	658

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Advisors's CLVS Position: Q4 2016 in Review

BlackRock Advisors increased its Clovis Oncology, Inc. (CLVS) stake by 24% in Q4 2016, buying an estimated $412K and bringing the position to 60,785 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1377.

BlackRock Advisors first reported a position in CLVS in Q2 2013 and has held it in 15 quarters since. The position peaked at $24.2M in Q3 2015. 167 funds tracked by Wall St. Rank hold CLVS as of Q4 2016.

BlackRock Advisors held 60,785 shares of Clovis Oncology, Inc. worth $2.7M as of Q4 2016.
BlackRock Advisors bought 11,692 Clovis Oncology, Inc. shares in Q4 2016, an estimated $412K.
Clovis Oncology, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1377 holding.
BlackRock Advisors first reported a position in Clovis Oncology, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Clovis Oncology, Inc. position peaked at $24.2M in Q3 2015.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.